Transfection Technologies Market

The transfection technologies market is projected to reach USD 1.8 billion by 2028 from an estimated USD 1.2 billion in 2023, at a CAGR of 9.4% during the forecast period. The major factors driving the growth of this transfection technologies market include increasing demand for cell and gene therapy, growing strategic alliances for the development of advanced therapeutic products, and increased technological advancement.

The global transfection technologies market is competitive with top players such as Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), and Merck KGaA (Germany). The market players have adopted various strategies such as new product/service launches, acquisitions, agreements, collaborations, and geographical expansions to strengthen their position in the global transfection technologies market.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific Inc. is a leading science and technology company engaged in manufacturing high-end analytical instruments, laboratory equipment, software, consumables, reagents, and services for scientific research, analysis, discovery, and diagnostics. It focuses on acquiring new consumers through partnerships, collaborations, and expansions in emerging markets like China, India, and South Korea. The company focuses on the adoption of strategic alliances to strengthen its footprints. For instance, in December 2021, Thermo Fisher Scientific Inc. acquired PPD, Inc. to expand the proposition for biotech and pharmaceutical customers.

Bio-Rad Laboratories, Inc. (US)

Bio-Rad Laboratories, Inc. manufactures and distributes specialty chemical products and services to the life science research, healthcare, analytical chemistry, biochemicals, and pharmaceutical markets.  The company focuses on life science markets such as cellular biology, genomics, proteomics, biopharmaceutical production, and food safety. Bio-Rad Laboratories, Inc. has a wide geographic presence across North America, Europe, Asia, and Latin America. The company is dedicating investments towards pioneering product development to propel a multi-generational pipeline for crucial product franchises. For instance, the company invested around USD 256.8 million for research and development activities in 2022.

QIAGEN (Netherlands)

QIAGEN is a leading global provider of sample technologies. The company offers products, digital tools, and platforms for several applications, such as research, diagnostics, clinical applications, and applied and industrial applications. The company has a wide global presence with 35 subsidiaries in over 25 countries and has a global distribution partner network in more than 60 countries. In addition, the company has a strong customer base across North America, Europe, the Asia Pacific, and the Middle East and Africa. Additionally, the company invested around USD 189.9 million in R&D.

Related Reports:

Transfection Technologies Market by Product (Kits, Equipment), Method (Physical (Electroporation, Microinjection), Biochemical (Lipofection, Calcium Phosphate), Viral), Application (Biomedical Research, Therapeutic Delivery) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]